Search Results - Emilio A. Emini

Refine Results
  1. 1
    Bivalent attachment of antibody onto poliovirus leads to conformational alteration and neutralization

    Bivalent attachment of antibody onto poliovirus leads to conformational alteration and neutralization by Emilio A. Emini, Philomena Ostapchuk, Eckard Wimmer

    Published 1983
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Guanidine-selected mutants of poliovirus: mapping of point mutations to polypeptide 2C

    Guanidine-selected mutants of poliovirus: mapping of point mutations to polypeptide 2C by S Pincus, David C. Diamond, Emilio A. Emini, Eckard Wimmer

    Published 1986
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide

    Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide by Emilio A. Emini, J V Hughes, Debra S. Perlow, Joshua Boger

    Published 1985
    Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    A novel assay for the DNA strand-transfer reaction of HIV-1 integrase

    A novel assay for the DNA strand-transfer reaction of HIV-1 integrase by Daria J. Hazuda, Jeffrey C. Hastings, Abigail Wolfe, Emilio A. Emini

    Published 1994
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Functional basis of poliovirus neutralization determined with monospecific neutralizing antibodies

    Functional basis of poliovirus neutralization determined with monospecific neutralizing antibodies by Emilio A. Emini, S Y Kao, Angela Lewis, R Crainic, Eckard Wimmer

    Published 1983
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Poliovirus neutralization epitopes: analysis and localization with neutralizing monoclonal antibodies

    Poliovirus neutralization epitopes: analysis and localization with neutralizing monoclonal antibodies by Emilio A. Emini, Bradford A. Jameson, Angela Lewis, G R Larsen, Eckard Wimmer

    Published 1982
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Drug Resistance and Predicted Virologic Responses to Human Immunodeficiency Virus Type 1 Protease Inhibitor Therapy

    Drug Resistance and Predicted Virologic Responses to Human Immunodeficiency Virus Type 1 Protease Inhibitor Therapy by Jon H. Condra, Christos J. Petropoulos, Rainer Ziermann, William A. Schleif, Malathi Shivaprakash, Emilio A. Emini

    Published 2000
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody

    Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody by Miroslaw K. Górny, Alan J. Conley, S Karwowska, Aby Buchbinder, Jiake Xu, Emilio A. Emini, Scott Koenig, Susan Zolla‐Pazner

    Published 1992
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody.

    Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. by Alan J. Conley, Joseph Kessler, L J Boots, J S Tung, Beth Arnold, Paul M. Keller, Alan Shaw, Emilio A. Emini

    Published 1994
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors

    Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors by Jon H. Condra, Emilio A. Emini, L Gotlib, Donald J. Graham, A J Schlabach, Jill Wolfgang, Richard J. Colonno, Vinod Sardana

    Published 1992
    Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Active human immunodeficiency virus protease is required for viral infectivity.

    Active human immunodeficiency virus protease is required for viral infectivity. by Nancy E. Kohl, Emilio A. Emini, William A. Schleif, Lenora J. Davis, Jill C. Heimbach, Richard A. Dixon, Edward M. Scolnick, Irving S. Sigal

    Published 1988
    Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors.

    Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors. by Vinod Sardana, Emilio A. Emini, L Gotlib, Donald J. Graham, D W Lineberger, William J. Long, A J Schlabach, Jill Wolfgang, Jon H. Condra

    Published 1992
    Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure

    Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure by Joseph K. Wong, Huldrych F. Günthard, Diane V. Havlir, Zhi‐Qiang Zhang, Ashley T. Haase, Caroline Ignacio, Shirley Kwok, Emilio A. Emini, Douglas D. Richman

    Published 1997
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors

    Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors by Jack H. Nunberg, William A. Schleif, Evelyn Boots, J A O'Brien, J C Quintero, J. M. HOFFMAN, Emilio A. Emini, Mark E. Goldman

    Published 1991
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells

    Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells by Robert L. LaFemina, Christine L. Schneider, Helen L. Robbins, P L Callahan, K LeGrow, E. Jill Roth, William A. Schleif, Emilio A. Emini

    Published 1992
    Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Safety and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Pediatric Vaccinations in Canada

    Safety and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Pediatric Vaccinations in Canada by Otto G. Vanderkooi, David W. Scheifele, Douglas Girgenti, Scott A. Halperin, Scott D. Patterson, William C. Gruber, Emilio A. Emini, Daniel A. Scott, James D. Kellner

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees

    Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees by Emilio A. Emini, Peter L. Nara, William A. Schleif, John A. Lewis, J P Davide, D R Lee, Joseph Kessler, S Conley, Shuzo Matsushita, Scott D. Putney

    Published 1990
    Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D

    Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D by Alan J. Conley, Miroslaw K. Górny, Joseph Kessler, L J Boots, M Ossorio-Castro, Scott Koenig, D W Lineberger, Emilio A. Emini, Constance Williams, Susan Zolla‐Pazner

    Published 1994
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

    Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine by Lisa A. Jackson, Alejandra Gurtman, Kathryn Rice, Karlis Pauksens, Richard N. Greenberg, Thomas R. Jones, Daniel A. Scott, Emilio A. Emini, William C. Gruber, Beate Schmöele-Thoma

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults

    Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults by Lisa A. Jackson, Alejandra Gurtman, Martin van Cleeff, Kathrin U. Jansen, Deepthi Jayawardene, Carmel Devlin, Daniel A. Scott, Emilio A. Emini, William C. Gruber, Beate Schmöele-Thoma

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: